Chief Editor
Sergio Harari has no potential conflicts of interest to disclose.
Editorial Board
Yochai Adir has no potential conflicts of interest to disclose.
Carlo Agostini has no potential conflicts of interest to disclose.
Piergiuseppe Agostoni has received personal fees from Menarini, Novartis and Boehringer Ingelheim, as well as grants from Daiichi Sankyo.
Katerina Antoniou has no potential conflicts of interest to disclose.
Sinthia Bosnic-Anticevich has received a previous research grant on inhaler device use from Teva Pharmaceuticals; a grant for seed funding for a pharmacy project on allergic rhinitis and a grant for an international research collaborative project on allergic rhinitis in pharmacy, from Meda Pharmaceuticals; a grant for an international collaboration regarding asthma management in primary care from Mundipharma; and personal consultancy fees for lectures from Teva Pharmaceuticals, AstraZeneca and GSK.
Antonella Caminati has received personal fees from Roche and Boehringer Ingelheim.
Rachel Chambers has no potential conflicts of interest to disclose.
Pascal Chanez has received fees for clinical trials from Boehringer Ingelheim. He has also received grants and personal fees for consultancy advisory board involvement and lecture fees from Almirall, Boehringer Ingelheim, Centocor, GlaxoSmithKline, AstraZeneca, Novartis, Teva, Chiesi and Schering Plough. He has also received personal fees for consultancy advisory board involvement and lecture fees from MSD and AMU.
Harold Collard has received personal fees from Medimmune, Bayer, Biogen, Boehringer Ingelheim, Xfibra, Genoa, Gilead, GlaxoSmithKline, Mesoblast, Moerae Matrix, PharmAkea, Promedior, Prometic, Pulmatrix, Pulmonary Fibrosis Foundation, Unity, Aeolus, aTyr pharmaceuticals, Pfizer, UCB Celltech, GBT, Veracyte, Patara, Samumed, Alkermes, Five Prime and Takeda.
Vincent Cottin has received personal fees for consultancy, lecture fees and reimbursement for attending meetings from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, Gilead, GSK, Intermune, MSD, Novartis, Pfizer, Roche and Sanofi. He has also received grants from Actelion, Boehringer Ingelheim, GSK, Pfizer and Roche, and personal fees from Boehringer Ingelheim for the development of educational presentations.
Steve Cunningham has received consultancy fees from Ablynx Pharmaceuticals and LFB Paris.
Anh Tuan Dinh-Xuan has no potential conflicts of interest to disclose.
Ralph Epaud has no potential conflicts of interest to disclose.
Francesco Forastiere has no potential conflicts of interest to disclose.
Mina Gaga has no potential conflicts of interest to disclose.
Bogdan Grigoriu has no potential conflicts of interest to disclose.
Felix Herth has received personal fees for lecture fees and advisory board involvement from Olympus, Uptake, BTG, Lilly, Grifols, Novartis, Astra Zeneca, TEVA, mundipharma, Boehringer Ingelheim, Boston Scientific, Broncus and medupdate.
Marc Humbert has relationships with drug companies including Actelion, Bayer, GSK, Novartis and Pfizer. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Martin Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic and Alkermes; grants from Actelion, Respivert and Synairgen; and personal fees from AstraZeneca and Genoa.
Tom Kotsimbos has no potential conflicts of interest to disclose.
Michael Kreuter has received speakers fees from Almirall, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, InterMune, Roche and Pfizer. He has also received research support from BMBF, DFG, Dietmar Hopp Stiftung, Eli Lilly, InterMune, Lungenfibrose e.V., Medac, Olympus, Rocheconsultant, UKGM and WATL, as well as consultancy fees from Boehringer Ingelheim and GlaxoSmithKline.
Edmund M.T. Lau has received personal fees for speaking and travel reimbursement from Actelion Pharmaceuticals and Menarini Pharmaceuticals.
Pierantonio Laveneziana has received personal fees for scientific board involvement from Novartis and travel and accommodation reimbursement from Chiesi.
Renaud Louis has no potential conflicts of interest to disclose.
Toby Maher has received personal fees from GlaxoSmithKline, Boehringer Ingelheim, InterMune, Lanthio, Sanofi-Aventis, AstraZeneca, Roche, Bayer, Biogen Idec, Cipla and ProMetic. He has received grants from Novartis and UCB, and institutional fees from Takeda, UCB and GlaxoSmithKline. He is also an investigator in an ongoing study for Gilead.
Marc Miravitlles has received personal fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, ESteve, GlaxoSmithKline, Menarini, Novartis, Grifols, Takeda, Gebro Pharma, MediImmune and CSL Behring.
Joel Moss has no potential conflicts of interest to disclose.
Chakaya J. Muhwa has no potential conflicts of interest to disclose.
Stefano Nava has no potential conflicts of interest to disclose.
Steeve Provencher has received grants and personal fees from Actelion Pharmaceuticals and Bayer, as well as grants from GSK.
Ganesh Raghu has no potential conflicts of interest to disclose.
Renata L. Riha has no potential conflicts of interest to disclose.
Carlos Robalo Cordeiro has no potential conflicts of interest to disclose.
Nicolas Roche has received grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GlaxoSmithKline, AstraZeneca, Chiesi, Mundipharma, Cipla, Sanofi, Sandoz, 3M and BRAHMS/Thermo Fischer scientific.
Laurent Savale has received personal fees and non-financial support from Actelion, Pfizer, Glaxosmithkline and Bayer.
Anita Simonds has no potential conflicts of interest to disclose.
Rogerio Souza has no potential conflicts of interest to disclose.
Nicola Sverzellati has no potential conflicts of interest to disclose.
Yuichi Tamura has received grants from Actelion, Nippon Shinyaku Pharmaceuticals and Mochida Seiyaku Pharmaceuticals.
Robert Vassallo has no potential conflicts of interest to disclose.
Geert Verleden has no potential conflicts of interest to disclose.